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In this chapter of the Evidence-based Practice Cen-
ters Methods Guide for Medical Tests, we describe how
the decision to use a medical test generates a broad
range of outcomes and that each of these outcomes
should be considered for inclusion in a systematic
review. Awareness of these varied outcomes affects
how a decision maker balances the benefits and risks
of the test; therefore, a systematic review should
present the evidence on these diverse outcomes. The
key outcome categories include clinical management
outcomes and direct health effects; emotional, social,
cognitive, and behavioral responses to testing; legal
and ethical outcomes, and costs. We describe the
challenges of incorporating these outcomes in a sys-
tematic review, suggest a framework for generating
potential outcomes for inclusion, and describe the role
of stakeholders in choosing the outcomes for study.
Finally, we give examples of systematic reviews that
either included a range of outcomes or that might have
done so. The following are the key messages in this
chapter:
& Consider both the outcomes that are relevant to the
process of testing and those that are relevant to the
results of the test.
& Consider inclusion of outcomes in all five domains:
clinical management effects, direct test effects; emo-
tional, social, cognitive and behavioral effects; legal and
ethical effects, and costs.
& Consider to which group the outcomes of testing are
most relevant.
& Given resource limitations, prioritize which outcomes to
include. This decision depends on the needs of the
stakeholder(s), who should be assisted in prioritizing the
outcomes for inclusion.
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BACKGROUND
The Agency for Healthcare Research and Quality (AHRQ)
requested production of a Methods Guide for Comparative
Effectiveness Reviews that specifically addresses the unique
challenges of preparing a systematic review of the use of a
medical test. This chapter describes the considerations
needed when selecting the outcomes that will be included
in a systematic review of a medical test. We describe in this
chapter the range of effects that medical tests have and how
these outcomes from testing should be incorporated into a
systematic review to make it maximally useful to those
using the review.
We define “decision-relevant” outcomes as the outcomes
that result from a testing encounter that may affect the
decision to use the test. We consider a broad range of
outcomes to illustrate how these may affect the balance of
the benefits and risks of the test. The outcomes to be
discussed are those that are relevant to screening tests,
diagnostic tests, and prognostic tests, although prognostic
tests are also discussed in Chapter 11. We also address
unique issues that might arise if the test in question is a
genetic test (although genetic tests are explored in more
detail in Chapter 10). We include a framework for
generating potential outcomes for inclusion, and discuss
the role of stakeholders in choosing the outcomes for study.
Finally, we give examples of systematic reviews that either
included a range of outcomes in the review or might have
done so.
COMMON CHALLENGES
Investigators are tasked with choosing the outcomes to
consider in a systematic review about a medical test.
Resource limitations require judicious selection from
among all possible outcomes, which necessitates setting
priorities for the outcomes to include. If reviewers do not
explore the full range of outcomes at the outset of the
project, the likelihood of excluding important outcomes is
high; the systematic review may miss outcomes relevant to
the stakeholder(s). The balance of the benefits and harms
from testing will be skewed by the absence of information
about key outcomes. The consequence may be that
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recommendations based on the systematic review are inapt
when the test is used in practice. Additionally, for tests that
offer modest clinical gains over another test, information on
additional outcomes may be essential for making decisions
with the results, like information about costs or conve-
nience. However, we caution that if the initially broad range
of outcomes is not carefully condensed, the quality of the
review will be threatened by resource limitations. (Fig. 1)
Either misstep can result in a suboptimal review—the
narrow review may be incomplete, and the broad review
may be too superficial to provide meaningful insights.
Principles for Addressing the Challenges
and Recommended Approaches
for Incorporating All Decision Relevant Outcomes
We recommend a two-step approach for choosing the
outcomes for inclusion in a review about a medical test.
The first step is to catalog outcomes methodically, and the
second is to solicit input from the stakeholder(s). Below is a
description of a conceptual approach to identifying out-
comes to ensure that relevant outcomes are not overlooked.
Principle 1: Catalog Outcomes Methodically
Conceptual Approach to Identifying Outcomes. The
preceding chapter included description of frameworks for
designing systematic reviews about medical tests that include
consideration of PICOTs (i.e., population, intervention,
comparisons, outcomes, timing, and setting). Here we
present another framework specifically for thinking about
the outcomes from using a test in a clinical setting. Here,
outcomes are separated into those attributable to the testing
process and those attributable to knowledge of the test
results. In general, outcomes attributable to the testing
process are direct effects of the test; outcomes attributable
to the test results are more plentiful and include the patient’s
response to the test results and how the patient and clinician
act upon the results.
Bossuyt and McCaffery described a useful framework for
thinking about patient outcomes attributable to medical
testing.1 They classified outcomes into three groups: (1)
outcomes that result from clinical management based on the
test results; (2) the direct health effects of testing; and (3)
the patients’ emotional, social, cognitive, and behavioral
responses to testing. We extend this model by including two
additional elements to arrive at five types of outcomes: (4)
the legal and ethical effects of testing, which may or may
not be a consideration depending on the test under
consideration; and (5) the costs of testing. These five
categories of outcomes can be associated with the testing
process, or with the test result, or with both.
We suggest that the relative importance of these out-
comes may differ substantially depending on the intention
of the test: screening, diagnosis, or prognosis (Table 1). To
illustrate, the adverse emotional effects, and the legal and
ethical outcomes of testing might be more significant for
medical tests used for screening than tests used for
diagnosis, due to the high prevalence of false positive test
results associated with many tests used for screening
purposes. Additionally, screening tests are conducted in
individuals who are without symptoms of the disease of
interest so any adverse or disruptive consequences of testing
may be more pronounced. Mammography is a useful
example since the emotional reaction to a false positive
test may be substantial. Correspondingly, the potential legal
consequences of a false negative test are substantial as a
false negative test may lead to the filing of a malpractice
suit. Missed diagnoses, in particular breast cancer diagno-
ses, are a large category of radiology-related malpractice
suits.2
Systematic reviewers should remember as well that a
normal test result, that is a test that has correctly excluded
the presence of disease, may be as affecting as a test that
has made a diagnosis, and inclusion of outcomes resulting
from a negative test may be important in the review. The
primary studies of the medical test may have assessed
behaviors and consequences after a normal test result,
which may include additional testing when a diagnosis is
sought or a change in behavior in response to a normal test
result (e.g., less attention to healthy lifestyle or possibly
redoubled efforts at maintaining good health). These are all
appropriate outcomes for consideration for inclusion in a
systematic review.
Figure 1. Balance of outcomes against resources.
Table 1. Outcomes that Might Be Particularly Consequential
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The impact of testing on clinical management is a more
important consideration when reviewing diagnostic testing
and less important for screening tests where the clinical
management may be quite removed from the screening step.
A useful example of diagnostic testing is the use of
computed tomography (CT) for detection of pulmonary
embolism: a positive test will result in many months of
anticoagulation therapy, an important clinical management
consequence for the patient. Therefore, systematic reviews
will ideally include primary literature that tests the clinical
consequences resulting from the use of CT in this setting
(rather than just the sensitivity and specificity and predictive
values of the test). It is likely that the direct health effects of
screening tests are less than in tests used for diagnosis and
prognosis: screening tests are generally designed to be less
invasive than tests used to make diagnoses in individuals
suspected of having disease. An example is PAP testing for
cervical cancer screening—there should be no direct health
effects of this process.
The range downstream activities that result from a test
are also appropriate for consideration as inclusion as
outcomes. These may be particularly prominent in imaging
tests where there is a high likelihood of identifying
unexpected findings that necessitate further evaluation
(e.g., unexpected adrenal masses seen during abdominal
imaging) or imaging tests that identify unexpected findings
that worry the patient (e.g., degenerative spine changes seen
on chest imaging). In these situations, one might consider
the emotional and cognitive outcomes of unexpected
findings, or the monetary costs of the downstream evalu-
ation of incidentally identified abnormalities.
Additional cost outcomes might be considered if appro-
priate to the systematic review. In addition to the direct
costs of the test, one might consider the downstream costs
triggered by the results of the testing that may include
confirmatory testing following a positive result, treatment
costs resulting from detecting disease, and costs for
treatment of adverse effects of the testing (direct harms of
the test and downstream harms resulting from additional
testing or treatment, or evaluation of incidental findings.)
Other costs to consider might be the costs to society from
direction of funds to testing and away from other services.
As an example, one might include, in a systematic review of
universal newborn screening, the impact of diverting
funding away from other childhood programs (such as
vaccination).
In addition to consideration of the consequences of
testing, we suggest that reviewers also consider an
additional axis; namely, who experiences the outcome.
The individual being tested is not the only one who can
experience outcomes from the testing process. Outcomes
may be experienced by family members, particularly in the
case of testing an index person for heritable conditions.
Outcomes may be experienced by the population away from
which resources are diverted by a screening activity, e.g.,
widespread newborn screening which diverts resources
away from population-based smoking cessation activities.
Society as a whole may experience some outcomes, as
when a test of an individual leads to a public health
intervention, e.g. prophylactic antibiotics or quarantine after
exposure to an infectious individual, or diversion of
resources in order to pay for testing of other individuals.
Payers are affected if they need to pay for a treatment of a
newly-diagnosed condition. (Fig. 2)
In summary, the range of outcomes that could be
included in a systematic review of a test is wide. We
encourage investigators doing systematic literature reviews
to think through this range of outcomes, considering the
testing process, the test results, the range of associated
outcomes, and the parties that may experience the out-
comes. These considerations may differ depending on the
type of test under consideration, as we discuss below, and
will differ importantly by the specific test and the question
being addressed by the systematic review.
Principle 2: Solicit input from Stakeholders
Stakeholders’ Role in defining the Outcomes and Guidance
from the Reviewers. Because the range of outcomes that a
reviewer might include is broad, expecting such reviews to
include “all possible outcomes” is unrealistic. The AHRQ
Methods Guide recommends that stakeholders be involved
at several steps in the systematic review process.3 We
describe additional considerations regarding the role of the
stakeholder in reviews of medical tests, as their inputs are
particularly relevant to the choice of outcomes for inclusion.
Little to no empiric evidence exists regarding what out-
comes are most essential for inclusion in a systematic
review. If the systematic reviewers knew that some out-
comes are universally valued by users of reports, these
would be routinely included. It is likely, however, that the
choice of outcomes depends largely on the needs of
stakeholders and how they intend to use the review.
Clinicians and patients are frequently the primary users of
the results of a systematic review and therefore are
important stakeholders in the process. An understanding
of what evidence the patient or clinician needs in order to
make a decision about use of the test is vital in selecting
outcomes for inclusion in a review. Certainly the health
effects of testing and the emotional or behavioral, social, or
cognitive outcomes are directly relevant to the patient; a
comprehensive review must include outcomes that are
important to patients and would influence their use of a test.
To give an example of another stakeholder, the Evalua-
tion of Genomic Applications in Practice and Prevention
(EGAPP) group of the Centers for Disease Control and
Prevention (CDC) has sponsored several EPC reports.4-6
EGAPP uses these reports to generate guidelines that the
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CDC issues about genetic testing. EGAPP’s interests are
broad; it aims to maximize the effectiveness of genetic
testing at a societal level. Understandably, the outcomes that
they consider to be relevant are broad and range from the
analytic validity of the test to the impact of the testing
process on family members. When the possible outcomes
for inclusion are many, the investigators have a responsi-
bility to work with the stakeholder to refine the questions
carefully so that the task can be accomplished.
Other stakeholders, like professional societies such as the
American College of Physicians, may be most interested in
evidence reports that can be used to generate recommenda-
tions or guidelines for practicing clinicians. Therefore, as
stakeholders, they may be more focused on how clinical
outcomes vary as a result of medical testing, and perhaps
less interested in outcomes that may be more relevant to
payers, such as cost-shifting to accommodate costs of
testing and downstream costs.
Not infrequently, the primary users of systematic reviews
are federal agencies such as the Center for Medicare &
Medicaid Services (CMS). This agency is responsible for
decisions regarding coverage of their beneficiaries’ medical
care, including medical tests. Therefore, CMS may specify
that the outcome most relevant to their coverage decision is
the analytic validity of the test, as it would not want to cover
a test that inadequately identifies the condition of interest.
The researchers doing comprehensive systematic reviews
have a role in helping stakeholders to understand the breadth
of outcomes. The researchers might assist stakeholders with
mapping the range of outcomes depicted in Figure 2. This
will allow the stakeholder to review the breadth of outcomes
and characterize the outcomes as being more or less vital
depending on the intended use of the review.
ILLUSTRATIONS
To explain these points in more detail, we use three
examples: one each of a screening test, a diagnostic test,
and a prognostic test. In discussing these examples, we
consider both outcomes that result from the process of
testing and outcomes associated with the results of testing,
and those that affect the tested individual and others. We
conclude with a discussion of additional considerations
when the test is a genetic test.
Example of a Screening Test. Screening tests are used to detect
disease in asymptomatic individuals or individuals with
unrecognized symptoms.7 Screening tests should be able to
separate individuals with the disease of interest from those
without, and should be employed when there is a treatment
available and where early treatment improves outcomes. The
US Preventive Services Task Force (USPSTF) develops
recommendations for use of clinical preventive services in
the United States. An EPC is sometimes tasked with preparing
the supporting review of the evidence.8,9 Other stakeholders
have interest in screening tests as well, including professional
organizations involved in guideline preparation for their
practitioners; cases in point are recommendations made by
the American College of Obstetrics and Gynecology regarding
cervical cancer screening10 and the American Cancer Society’s
recommendations for early cancer detection.11
To illustrate outcomes in a systematic review of a
screening test, we present the example of a systematic
review about screening for bacterial vaginosis in pregnant
women.12 This systematic review was first done for the
USPSTF in 2001 and was later updated. Figure 3 depicts
the analytic framework developed by the authors.
Clinical Management Effects. The authors addressed whether
screening for bacterial vaginosis during pregnancy in
asymptomatic women reduces adverse pregnancy
outcomes. They included a review of the clinical
management effects that would result from antibiotic
treatment based on screening results. These included
adverse effects of therapies and the beneficial effects of
reduction in adverse pregnancy outcomes, such as preterm
delivery. The authors might also have explicitly included an
Figure 2. Mapping outcomes to the testing process and to the test results.
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outcome that examines whether the screening leads to
receipt of antibiotic treatment—whether screening leads to a
change in clinical management. This would be a relevant
intermediate outcome on the path between screening and
the outcomes attributable to therapy.
Direct Test Effects. Appropriately, the authors of this review
did not include outcomes that are a direct result of the
testing process because direct test effects are unlikely in this
example; a vaginal swab will not cause any injury.
Similarly, the test does not confer any direct benefit either
except perhaps contact with clinicians.
Emotional, Social, Cognitive, or Behavioral Effects. The authors
might have also looked at the emotional, social, cognitive, or
behavioral effects from the screening process or from the
screening test results. It may have been appropriate to
consider outcomes that are associated with screening but
are not the result of antibiotic therapy. Consideration may
have been given to the effects of testing positive for bacterial
vaginosis, such as emotional responses to a diagnosis of
infection leading to either healthier or riskier prenatal
activities, or maternal worry as an outcome.
As with any measure, the systematic review team might
require that the instrument used to measure emotional
response be a validated and appropriate instrument.
Legal and Ethical Effect of Testing. Although specifying
ethical issues in screening for bacterial vaginosis (which is
not a sexually transmitted infection) may seem unnecessary,
bacterial vaginosis testing may be done as part of an
infectious disease screening for reportable diseases such as
syphilis or HIV. Therefore, a review of the effects of testing
should consider whether the test being reviewed might be
administered with concurrent screening tests that could
themselves raise ethical issues.
Costs of the Test. The authors of this review did not consider
the costs of the test to the patient as an outcome.
Widespread initiation of screening programs, such as on a
population level, may have profound cost implications.
The authors of this review considered the effects of
screening on the mother and on the fetus or infant. However,
they might have also considered other relevant parties; these
might include the mother’s partner and society, as antibiotic
resistance is a conceivable outcome from widespread testing
and treatment of bacterial vaginosis.
Example of a Diagnostic Test. We differentiate diagnostic tests
from screening tests largely by the population being tested.
Whereas a diagnostic test is applied to confirm or refute
disease in a symptomatic person, a screening test is used in an
asymptomatic or pre-symptomatic person. The USPSTF
mostly makes recommendations about screening tests that
may be used in the general population; other organizations are
more concerned with ensuring safe use of diagnostic tests in
patient populations. Payers are also interested in optimizing
use of diagnostic tests, as many are costly.
Figure 3. Screening example: bacterial vaginosis.
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We discuss a review that addressed the diagnostic value
of 64-slice computed tomography (CT) in comparison to
conventional coronary angiography.13 Stating that their
review concerned the “accuracy” of CT, the authors aimed
to assess whether 64-slice CT angiography might replace
some coronary angiography for diagnosis and assessment of
coronary artery disease. A broader review may consider the
effectiveness of CT angiography, and the investigators
would consider the full range of outcomes as below.
Clinical Management Effects. Numerous cl inical
management effects might follow testing for coronary
artery disease with CT. The authors of the review focused
exclusively on detection of occluded coronary arteries and
not on any downstream outcomes from identification of
occluded coronary arteries. Individuals diagnosed with
coronary artery disease are subjected to many clinical
management changes; these include medications,
recommendations for interventions such as angioplasty or
bypass surgery, and recommendations for lifestyle
changes; each of which has associated benefits and
harms. All of these may be appropriate outcomes to
include in evaluating a diagnostic test. If one test under
consideration identifies more coronary artery disease than
another, this will be reflected in clinical management
changes and their consequences.
Other conceivable clinical management effects relate to the
impact of testing on other health maintenance activities. For
example, a patient might defer other necessary testing (e.g.,
bone densitometry) to proceed with the CT. We would
expect, however, that this would also be the case in the
comparison arm. Family members may be affected as well by
testing; for instance, they may be called upon to assist the
diagnosed patient with future appointments, which may
necessitate time away from work and cause emotional stress.
Direct Test Effects. The test under consideration is a
radiographic test. It confers no direct benefit itself (unlike
the comparison procedure in which an intervention can be
performed at the time of conventional diagnostic
angiography). The testing process poses potential harms,
including allergic reaction to the intravenous contrast
material, renal failure from the contrast material, and
radiation exposure. These are all outcomes that could be
considered for inclusion. In this example, the comparison
test carries comparable or greater risks.
Emotional, Social, Cognitive, or Behavioral Effects. The testing
process itself is unlikely to have significant emotional
consequences, as it is not an invasive test and is generally
comfortable for the tested individual. The results of testing
could indeed have emotional or behavioral consequences.
An individual diagnosed with coronary disease might alter
his or her lifestyle to reduce disease progression. On the
other hand, an individual might become depressed by the
results and engage in less self-care or riskier behavior.
These behavioral effects are likely to affect the family
members as well. However, in this example the emotional
or behavioral effects are expected to be similar for both CT
and conventional angiography and therefore may not be
relevant for this particular review. In contrast, they would
be relevant outcomes if CT angiography were being
compared with no testing.
Legal and Ethical Effects of Testing. Testing could have legal
consequences if the tested individual is in a profession that
requires disclosure of health threats for the safety of the
public; this might arise if, e.g., the tested person were an
airline pilot. However again, this outcome is not expected to
differ between CT and conventional angiography.
Costs of the Test. The relative costs of the two tests to the
insurer and the patient, and the costs of diverting equipment
away from other uses, could also be of interest to some
stakeholders.
Outcomes Unique to Prognostic Tests. Prognostic tests are
tests used in individuals with known disease to predict
outcomes. The procedure itself may be identical to a
procedure that is used as a screening test or a medical
test, but the results are applied with a different purpose.
Given this, additional considerations for outcomes should
be included in reviews. For example, consider the use of
spirometry for predicting prognosis in individuals with
chronic obstructive pulmonary disease (COPD). The test is
commonly used for making the diagnosis of COPD and
monitoring response to treatment, but the question has been
raised as to whether it might also predict survival. In 2005,
the Minnesota EPC did a systematic review of this topic on
behalf of the American Thoracic Society, American College
of Physicians, American Academy of Family Physicians,
and American Academy of Pediatrics.14 The discussion
below focuses on one of their key questions, which was
whether prediction of prognosis with spirometry, with or
without clinical indicators, is more accurate than prediction
based on clinical indicators alone. They were interested in
predicting survival free of premature death and disability.
Clinical Management Effects. The results from prognostic
testing will have effects on clinical management. Although
the prognoses for some diseases are minimally modifiable
with current treatments, most prognostic information can be
used to alter the course of treatment. In this example,
spirometry may suggest a high likelihood of progressing to
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respiratory failure and prompt interventions to avert this
(e.g., pulmonary rehabilitation efforts, changes in
medication, avoidance of some exposures). Conversely,
the prognostic information may be used to make decisions
regarding other interventions. If the likelihood of dying of
respiratory failure is high, patients and their physicians may
choose to refrain from colonoscopy and other screening
procedures from which the patient is unlikely to benefit.
Similarly, treatments of other conditions may be of less
interest if life expectancy is short.
Direct Test Effects. Spirometry has few direct test effects,
although patients can have adverse reactions to testing
particularly if challenged with methacholine as part of the
test. In general, it is unlikely that tests used for prognosis
are more or less likely to have direct test effects than tests
used for other purposes.
Emotional, Social, Cognitive, or Behavioral Effects. We doubt
that many emotional or cognitive effects would arise in
response to the testing process. Spirometry is a noninvasive
test that most patients tolerate well. Emotional effects to the
results of testing are possible; emotional effects could even
be more pronounced for prognostic tests than for screening
or medical tests if the test yields more specific information
about mortality risk than is usual from a diagnostic test.
This could have a range of effects on behavior including
efforts to alter prognosis, like smoking cessation. Test
results with prognostic information would be expected to
affect family members as well.
Legal and Ethical Effects of Testing. Results of tests that
provide prognostic information could have legal outcomes,
too, especially if the tested individual acts in ways that belie
the information he has received (e.g., entering into a
contract or relationship that he is unlikely to fulfill). In
this present example, it is unlikely that the prognostic
information from spirometry would actually raise these
issues, but in other cases, such as a test that demonstrates
widely metastatic cancer, this could be an issue. These legal
and ethical effects of testing may reach beyond the tested
individual and affect society if many individuals have
substantial concealed information that influences their
actions.
Costs of the Test. The relative costs of the test to the insurer
and the patient, relative to the costs of collecting
information from a history and physical examination, may
all be of interest to stakeholders.
If the Test is a Genetic Test. Chapter 10 of this guide describes
in detail unique issues regarding evaluation of genetic tests.
With respect to relevant outcomes, we note a few
considerations here. Most prominent is the effect on
family members. Genetic information about the tested
individual has direct bearing on family members who
share genes. This may affect emotional and behavioral
outcomes, and ethical outcomes, if family members feel
pressured to proceed with testing to provide better
information for the rest of the family. A second issue is
possible impact of health insurance eligibility. Recent
legislation in the United States prohibits the use of genetic
test results to exclude an individual from health insurance
coverage, making this less a relevant outcome than in the
past. This policy varies worldwide, however, and may be a
relevant consideration in some countries.
SUMMARY
In specifying and setting priorities for outcomes to address
in their systematic reviews, investigators should:
& Consider both outcomes that are relevant to the process of
testing and those that are relevant to the results of the test.
& Consider inclusion of outcomes in all five domains:
clinical management effects, direct test effects; emo-
tional, social, cognitive and behavioral effects; legal and
ethical effects, and costs.
& Consider to which group the outcomes of testing are
most relevant.
& Given resource limitations, prioritize which outcomes to
include. This decision depends on the needs of the
stakeholder(s), who should be assisted in prioritizing the
outcomes for inclusion.
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